Compared to AKI, treatment with EVs alone significantly reduced the levels of all three injury markers (BUN 150.23 ± 9.26 vs. 72.23 ± 5.61 mg/dL, p < 0.05; SCr 1.83 ± 0.08 vs. 0.99 ± 0.01 mg/dL, p < 0.05; NGAL 4.53 ± 0.68 vs. 2.11 ± 0.33 mg/mL, p < 0.05), and the combined treatment of pFUS + EVs further reduced all these markers compared to treatment with EVs alone (BUN 50.74 ± 3.34 vs. 72.23 ± 5.61 mg/dL, p < 0.05; SCr 0.61 ± 0.02 vs. 0.99 ± 0.01 mg/dL, p < 0.05; NGAL 1.70 ± 0.42 vs. 2.11 ± 0.33 mg/mL, p > 0.05). This evidence concerns the gene LCN2 and acute kidney injury.